Evidence map›Paper›PMID 40910183›Full record

Trial reportJournal of diabetes2025

Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial.

Shujing Wu, Huajie Xu, Lili Xu, Huanyi Zhang, Kang Cheng, Xiaoyan Wang, Manhua Chen, Guangping Li, Jiangnan Huang, Jun Lan and 7 more

Abstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shujing WuDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
Huajie XuDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
Lili XuDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
Huanyi ZhangDepartment of Cardiology, Taian City Central Hospital, Taian, China.
Kang ChengDepartment of Cardiology, Xi'an no. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, China.
Xiaoyan WangDepartment of Cardiology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Manhua ChenDepartment of Cardiology, The Central Hospital of Wuhan, Wuhan, China.
Guangping LiDepartment of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Jiangnan HuangDepartment of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jun LanDepartment of Cardiology, Dongguan Third People's Hospital, Dongguan, China.
Guanghe WeiDepartment of Cardiology, Affiliated Hospital of Jining Medical University, Jining, China.
Xin ZhaoDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
Zhiyong QiDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
Juying QianDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
Hongyi WuDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-4773-1962
Junbo GeDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
OPTION investigators

Funding

Clinical Research Special Fund of Zhongshan Hospital Fudan University 2020ZSLC57Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd NANational Natural Science Foundation of China General Program 81970298Research Project of Shanghai Municipal Health Commission 20214Y0139Shanghai Clinical Research Center for Interventional Medicine 19MC1910300
6 · The paper itself

Abstract

backgroundDespite increased risk of ischemic events in diabetes, the optimal anti-thrombotic strategy for secondary prevention has not been defined. We aimed to assess the efficacy and safety of optimal antiplatelet agents such as indobufen-based dual antiplatelet therapy (DAPT) in patients with diabetes after coronary stenting.

methodsOPTION trial was a randomized, open-label, noninferiority, and multicentric study in China. Enrolled subjects were randomized 1:1 to indobufen-based DAPT or aspirin-based DAPT. This post hoc analysis from OPTION trial was performed by the presence of diabetes. The primary endpoint was a 1-year composite of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, definite or probable stent thrombosis, or Bleeding Academic Research Consortium (BARC) criteria type 2, 3, or 5 bleeding.

resultsOf 4551 OPTION patients, the primary endpoint occurred in 93/1570 patients with diabetes (5.92%), as compared to 148/2981 without diabetes (4.96%) (HR: 0.72, 95% CI: 0.47-1.08, and HR: 0.73, 95% CI: 0.53-1.01, respectively), without significant interaction between diabetes status and treatment effect (P

conclusionsIn patients receiving DES implantation, indobufen-based DAPT might be considered as a reasonable alternative to aspirin-based DAPT in the secondary prevention for those with diabetes, especially in patients at high bleeding risk.

Indexed as

AspirinClopidogrelCoronary Artery DiseaseDiabetes MellitusPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsStentsAgedChinaDrug Therapy, CombinationDual Anti-Platelet TherapyFemaleHumansMaleMiddle AgedSecondary PreventionAspirinClopidogrelPlatelet Aggregation Inhibitorsaspirincoronary artery diseasediabetesdual antiplatelet therapyindobufenpercutaneous coronary intervention

Identifiers

PMID40910183
PMCPMC12411781

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.